Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Aug;9(3):e003317.
doi: 10.1136/rmdopen-2023-003317.

The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis

Alan Kivitz  1 , Liangwei Wang  2 , Ilias Alevizos  2 , Michele Gunsior  2 , Judith Falloon  2 , Gabor Illei  2   3 , E William St Clair  4
Affiliations
Clinical Trial

The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis

Alan Kivitz et al. RMD Open. 2023 Aug.

Erratum in

Abstract

Objectives: To evaluate the safety, efficacy and response duration of four different dosing regimens of dazodalibep (DAZ), a non-antibody biological antagonist of CD40L, in patients with rheumatoid arthritis (RA).

Methods: This double-blind study included adult patients with moderate-to-severe active RA with a positive test for serum rheumatoid factor and/or anticitrullinated protein antibodies, an inadequate response to methotrexate, other conventional disease-modifying antirheumatic drugs or tumour necrosis factor-α inhibitors, and no prior treatment with B-cell depleting agents. Eligible participants were randomised equally to five groups receiving intravenous infusions of DAZ or placebo. The primary endpoint was the change from baseline in the Disease Activity Score-28 with C reactive protein (DAS28-CRP) at day 113. Participants were followed through day 309.

Results: The study randomised 78 eligible participants. The change from baseline in DAS28-CRP (least squares means±SE) at day 113 was significantly greater for all DAZ groups (-1.83±0.28 to -1.90±0.27; p<0.05) relative to PBO (-1.06±0.26); significant reductions in DAS28-CRP were also observed for all DAZ groups at day 309. The distribution of adverse events was generally balanced among DAZ and PBO groups (74% and 63%, respectively). There were four serious adverse events deemed by investigators to be unrelated to study medication.

Conclusions: DAZ treatment for all dosage regimens significantly reduced DAS28-CRP at day 113 relative to PBO. The safety data suggest an acceptable safety and tolerability profile. Treatment effects at day 113 and the prolonged duration of responses after DAZ cessation support the use of longer dosing intervals.

Trial registration number: NCT04163991.

Keywords: arthritis, rheumatoid; pharmacokinetics; therapeutics.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AK has received study funding, medical writing support, and article processing charges from Amgen. He has received consulting fees from AXDEV Group, Pfizer, Janssen, Boehringer Ingelheim, AbbVie, Flexion, Gilead, Grunenthal, Orion, Regeneron, Sun Pharma Advance Research, and ECOR1. He has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Merck & Co, Eli Lilly, Novartis, Pfizer, Flexion, AbbVie, Amgen, Genentech, Regeneron, UCB, Horizon, and GSK. He has participated in a data safety monitoring board for AbbVie and Amgen. He has been part of a board or advisory board for AbbVie, Bendcare, Boehringer Ingelheim, ChemoCentryx, Flexion, Gilead, Grunenthal, Horizon, Eli Lilly, Janssen, Pfizer, Regeneron, UCB, and Novartis. He has stock or stock options in Pfizer, GSK, Gilead, Novartis, and Amgen. LW, IA are current employees of Horizon Therapeutics and own stock. MG, JF and GI are former employees of Horizon Therapeutics and own stock. EWS has consulted for Horizon Therapeutics, Bristol Myers Squibb, CSL Behring, Resolve Therapeutics, and Sonoma Biotherapeutics, and receives royalties from UpToDate.

Figures

Figure 1
Figure 1
Disposition of MIDORA participants. Data reported as n (%). DAZ, dazodalibep.
Figure 2
Figure 2
Change from baseline in DAS28-CRP. (A) MMRM results for DAS28-CRP at day 113 and day 309; *p<0.1; **p<0.05; ***p<0.01. (B) Change from baseline in DAS28-CRP plotted by study visit. DAS28-CRP, Disease Activity Score in 28 joints using C reactive Protein; DAZ, dazodalibep; LS, least squares; MMRM, mixed model for repeated measures.
Figure 3
Figure 3
Concentration-time profile of DAZ. The mean (±SD) concentration-time profiles of DAZ following intravenous infusion. DAZ, dazodalibep.
Figure 4
Figure 4
DAZ biomarkers. Line plots of DAZ biomarkers by study visit for (A) RF, (B) ACPA, (C) total sCD40L and (D) CXCL13. ACPA, anticitrullinated protein antibody; CXCL13, C-X-C motif chemokine ligand 13; DAZ, dazodalibep; MAD, median absolute deviation; RF, rheumatoid factor; sCD40L, soluble CD40L.
See this image and copyright information in PMC

References

    1. Karnell JL, Rieder SA, Ettinger R, et al. Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond. Adv Drug Deliv Rev 2019;141:92–103. 10.1016/j.addr.2018.12.005 - DOI - PubMed
    1. Daoussis D, Antonopoulos I, Andonopoulos AP, et al. Increased expression of CD154 (CD40L) on stimulated T-cells from patients with psoriatic arthritis. Rheumatology (Oxford) 2007;46:227–31. 10.1093/rheumatology/kel229 - DOI - PubMed
    1. Desai-Mehta A, Lu L, Ramsey-Goldman R, et al. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 1996;97:2063–73. 10.1172/JCI118643 - DOI - PMC - PubMed
    1. Croft M, Benedict CA, Ware CF. Clinical targeting of the TNF and TNFR Superfamilies. Nat Rev Drug Discov 2013;12:147–68. 10.1038/nrd3930 - DOI - PMC - PubMed
    1. Banchereau J, Dubois B, Fayette J, et al. Functional Cd40 antigen on B cells, Dendritic cells and fibroblasts. Adv Exp Med Biol 1995;378:79–83. - PubMed

Publication types

Associated data